niacinamide has been researched along with ruthenium in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doro, FG; Rodrigues-Filho, UP; Tfouni, E | 1 |
| Bregman, H; Marmorstein, R; Meggers, E; Pagano, N; Qin, J; Streu, C; Xie, P | 1 |
| Bi, W; Liang, G; Liang, Y; Yan, H | 1 |
| Atil, B; Berger, W; Groza, D; Heffeter, P; Jungwirth, U; Keppler, BK; Koellensperger, G; Körner, W; Kryeziu, K; Mohr, T | 1 |
| Chen, MW; Li, X; Zhao, ZB; Zhao, ZK; Zhou, YG | 1 |
5 other study(ies) available for niacinamide and ruthenium
| Article | Year |
|---|---|
A regenerable ruthenium tetraammine nitrosyl complex immobilized on a modified silica gel surface: preparation and studies of nitric oxide release and nitrite-to-NO conversion.
Topics: Amines; Niacinamide; Nitric Oxide; Nitrites; Organometallic Compounds; Ruthenium; Silica Gel; Silicon Dioxide | 2007 |
The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase.
Topics: Animals; Benzenesulfonates; Cell Cycle Proteins; Crystallography, X-Ray; Humans; Ligands; Mice; Models, Molecular; Molecular Chaperones; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Ruthenium; Sorafenib | 2009 |
[Hydrolytic property and solution stability of NAMI derivative containing nicotinamide].
Topics: Dimethyl Sulfoxide; Drug Stability; Hydrolysis; Imidazoles; Kinetics; Ligands; Niacinamide; Ruthenium; Solutions | 2012 |
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Synergism; Female; Heterografts; Humans; Mice; Mice, SCID; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Ruthenium; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Biomimetic asymmetric reduction of benzoxazinones and quinoxalinones using ureas as transfer catalysts.
Topics: Benzoxazines; Biomimetic Materials; Catalysis; Cell Cycle Proteins; Coordination Complexes; Hydrogen Bonding; Models, Chemical; Molecular Conformation; NAD; Niacinamide; Oxidation-Reduction; Quinoxalines; Ruthenium; Substrate Specificity; Transcription Factors; Urea | 2020 |